Pneumocystis jirovecii nucleic acids and nucleic acid-processing enzymes

Pneumocystis jirovecii nucleic acids and their associated processing enzymes represent a critical set of therapeutic targets for treating Pneumocystis pneumonia (PCP), a life-threatening infection in immunocompromised individuals. This target group includes the fungal DNA and RNA themselves, as well as essential enzymes such as dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR), which are required for the synthesis of folate precursors necessary for nucleotide production. Drugs like trimethoprim and sulfamethoxazole work synergistically to inhibit these enzymes, thereby halting DNA synthesis and fungal replication. Other agents, such as pentamidine, are thought to bind directly to the minor groove of the fungal DNA, interfering with both replication and transcription processes. Because these pathways are fundamental to the pathogen's survival and proliferation, they remain the primary focus of current antimicrobial strategies. However, drug resistance—particularly mutations in the DHPS gene—is an emerging clinical concern that complicates the management of PCP. Understanding these targets is also essential for molecular diagnostics, as PCR-based detection of P. jirovecii nucleic acids is the gold standard for diagnosis.

Other names

Pneumocystis jirovecii DNAPneumocystis jirovecii RNAPneumocystis jirovecii folate synthesis enzymesPneumocystis jirovecii replication machinery

Inhibition of dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR) to disrupt folate synthesis; direct binding to the minor groove of DNA to inhibit replication and transcription.